GLP-1 medications are now available in both tablet and injection forms, offering two different ways to access the same hormone-based treatment approach for weight management.
While they work through similar pathways to reduce appetite and support weight loss, they differ in how they are taken, how the body absorbs them, and the results seen in clinical studies.
Tablets are not inherently better or worse than injections. GLP-1 tablets avoid needles and may be easier to store and travel with, while injections generally require less frequent dosing. Effectiveness depends more on the medicine and dose than the route of administration. Among current treatments, tirzepatide injections have produced greater average weight loss than licensed oral GLP-1 medicines in separate clinical trials.
| Factor | GLP-1 tablets | Weight-loss injections |
|---|---|---|
| Frequency | Usually daily | Usually weekly |
| Needles | No | Yes |
| Food restrictions | Depends on medicine | Generally none |
| Refrigeration | Usually not required | Often required before use |
| Absorption | Through gastrointestinal tract | Subcutaneous |
| UK-licensed examples | Wegovy tablets, Foundayo | Wegovy, Mounjaro |
| Best clinical-trial results among currently licensed options | Around 12–17% depending on analysis | Up to around 21–23% depending on medicine/analysis |
| Suitable for travel | Potentially easier | May require more storage planning |
| Head-to-head evidence | Limited | – |
The key difference lies in how the medicine is formulated and taken.
GLP-1 tablets are taken by mouth. They are specifically formulated to help the medicine survive the digestive system and be absorbed through the stomach.
GLP-1 injections are given under the skin using a pre-filled pen. This route bypasses the digestive system and allows the medicine to be absorbed from the tissue under the skin into the circulation over time.
Once absorbed, it acts on GLP-1 receptors to reduce hunger, slow digestion, and support blood sugar control.
Injectable weight loss treatments do not all work on exactly the same receptors. Their mechanism depends on the active ingredient.
There is no single winner based purely on whether the medicine is a tablet or an injection. The mechanism is determined by the active ingredient, not the route of administration.
That said, current injectable options include medicines with broader receptor activity, such as Mounjaro and investigational retatrutide. This is one reason injections currently have the edge in weight loss results. However, tablets may still be highly effective when they are properly absorbed and taken consistently.
Dosing depends on the specific medication.
| Treatment | Type / mechanism | Typical dosing (highest studied / approved) |
|---|---|---|
| Wegovy tablet | GLP-1 | Once daily dosing up to 25mg once daily |
| Foundayo | GLP-1 | Once-daily dosing studied across ranges up to 17.2mg once daily |
| Wegovy injection | GLP-1 | 0.25mg weekly, gradual increase to 7.2mg once weekly |
| Mounjaro | GIP + GLP-1 | Up to 15mg once weekly |
| Retatrutide | GLP-1 + GIP + glucagon | Early trials used 2–12mg once weekly range (dose still under investigation) |
For more information about treatment dosage schedule’s, visit:
The key difference is how structured the routine is.
Injections are usually taken once weekly using a pre-filled pen. They are injected under the skin and can generally be taken at any time of day, with or without food.
This makes the weekly injection routine less dependent on mealtimes, morning schedules or other oral medicines.
From a practical point of view, tablets feel simpler in the moment, but injections are often easier to stay consistent with long term.
| Treatment | Route | Main study | Duration | Main average weight-loss figure |
|---|---|---|---|---|
| Foundayo | Tablet | ATTAIN-1 | 72 weeks | ~12.4%* |
| Wegovy 25mg | Tablet | OASIS 4 | 64 weeks | 13.6% |
| Wegovy 2.4mg | Injection | STEP 1 | 68 weeks | 14.9% |
| Wegovy 7.2mg | Injection | STEP UP | 72 weeks | 18.7% |
| Mounjaro 15mg | Injection | SURMOUNT-1 | 72 weeks | ~20.9% |
| Retatrutide 12mg | Injection | TRIUMPH-4 | 68 weeks | 28.7%** |
Current and investigational injectable weight-loss options include dual- and triple-receptor medicines, which is why some injectable treatments have produced higher average weight loss in clinical trials. The difference is primarily driven by the medicine, dose and mechanism, not simply whether it is swallowed or injected.
This helps explain why some injectable medicines have produced greater average weight loss in clinical trials. The difference is primarily driven by the medicine, dose and mechanism rather than simply whether it is swallowed or injected.
These are not head-to-head studies.
Trial design, participant characteristics, doses and statistical methods differed, so the percentages should not be interpreted as proving that one treatment is a specific percentage more effective than another.
Both tablets and injections in the GLP-1 class commonly share similar side effects. The most frequently reported include:
The frequency and severity of side effects vary according to the individual medicine, dose and stage of dose escalation rather than simply whether the treatment is taken as a tablet or injection.
Injectable treatments can additionally cause injection-site reactions such as redness, itching or swelling.
Rare but important risks include pancreatitis, gallbladder problems, dehydration from severe vomiting/diarrhoea, and potential worsening of diabetic eye disease in people with diabetes. These are uncommon but require medical attention if symptoms occur.
Neither route can be said to consistently cause fewer side effects. The side-effect profile depends more on the specific medicine and dose. Both oral and injectable GLP-1-based treatments commonly cause gastrointestinal side effects, while injections can additionally cause injection-site reactions.
Prices start from £88.99 per month
Prices start from £84.99 per month.
Chemist Click pricing is:
| Dose | Price |
|---|---|
| 0.25mg | £93.99 |
| 0.5mg | £97.99 |
| 1mg | £107.99 |
| 1.7mg | £136.99 |
| 2.4mg | £175.99 |
| 7.2mg | £552.40 |
Chemist Click pricing is:
| Dose | Price |
|---|---|
| 2.5mg | £143.99 |
| 5mg | £153.99 |
| 7.5mg | £212.99 |
| 10mg | £239.99 |
| 12.5mg | £259.99 |
| 15mg | £279.49 |
Further reading: Where to buy retatrutide
At present, tablets are not commercially priced for weight-loss use, so injections are the only real-cost option on the market, with Wegovy generally being slightly cheaper than Mounjaro in private UK pricing.
Both Foundayo and Wegovy tablets are available in the UK.
Both Wegovy and Mounjaro are available in the UK. Retatrutide is undergoing clinical trials and is not available.
GLP-1 tablets may be better for you if:
Injections may be better for you if:
Not necessarily. Injectables like Wegovy and Mounjaro tend to show higher average weight loss in studies, but tablets such as oral semaglutide can still be effective and may suit people who prefer not to use injections.
Yes, in some cases a clinician may switch you from injections to tablets or vice versa. For example, you can switch from Wegovy injections to tablets after a 7-day washout period.
Not necessarily.
Wegovy tablets and Wegovy injections both contain semaglutide. Their standard clinical trial results are relatively similar.
Mounjaro performs better largely because tirzepatide activates GIP as well as GLP-1, not simply because it’s injected.
Whilst all of our content is written and reviewed by healthcare professionals, it is not intended to be substituted for or used as medical advice. If you have any questions or concerns about your health, please speak to your doctor.